| 29.02 -0.28 (-0.96%) | 12-05 10:01 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.48 | 1-year : | 42.42 |
| Resists | First : | 32.94 | Second : | 36.31 |
| Pivot price | 29.02 |
|||
| Supports | First : | 27.48 | Second : | 22.87 |
| MAs | MA(5) : | 29.15 |
MA(20) : | 29.85 |
| MA(100) : | 29.14 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 43.8 |
D(3) : | 36.2 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 36.45 | Low : | 25.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALKS ] has closed below upper band by 48.0%. Bollinger Bands are 55.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 29.69 - 29.86 | 29.86 - 30.02 |
| Low: | 28.57 - 28.75 | 28.75 - 28.92 |
| Close: | 29.03 - 29.33 | 29.33 - 29.6 |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Thu, 04 Dec 2025
ALKS: Elixirxton demonstrates strong efficacy, safety, and dosing flexibility for narcolepsy and hypersomnolence - TradingView
Wed, 03 Dec 2025
Mackenzie Financial Corp Acquires 53,323 Shares of Alkermes plc $ALKS - MarketBeat
Mon, 01 Dec 2025
Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Mon, 01 Dec 2025
Rhumbline Advisers Purchases 17,660 Shares of Alkermes plc $ALKS - MarketBeat
Mon, 01 Dec 2025
Legal & General Group Plc Sells 17,227 Shares of Alkermes plc $ALKS - MarketBeat
Tue, 25 Nov 2025
Alkermes to Participate in Two Upcoming Investor Conferences - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 165 (M) |
| Shares Float | 163 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 106.1 (%) |
| Shares Short | 17,300 (K) |
| Shares Short P.Month | 14,400 (K) |
| EPS | 2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.5 |
| Profit Margin | 22.2 % |
| Operating Margin | 22.6 % |
| Return on Assets (ttm) | 9.9 % |
| Return on Equity (ttm) | 22.3 % |
| Qtrly Rev. Growth | 4.1 % |
| Gross Profit (p.s.) | 7.93 |
| Sales Per Share | 9.2 |
| EBITDA (p.s.) | 2.35 |
| Qtrly Earnings Growth | -12.2 % |
| Operating Cash Flow | 541 (M) |
| Levered Free Cash Flow | 342 (M) |
| PE Ratio | 14.45 |
| PEG Ratio | 0 |
| Price to Book value | 2.76 |
| Price to Sales | 3.15 |
| Price to Cash Flow | 8.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|